首页> Archives of dermatological research> Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study.

Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study.

导出原文传递

翻译打印收藏纠错

第一作者： Natalia,Rompoti

第一单位： 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, I. Dragoumi 5, Athens, 161 21, Greece.

作者： Natalia,Rompoti ^[1] ; Ioannis-Alexios,Koumprentziotis ^[2] ; Irene,Stefanaki ^[1] ; Charitomeni,Vavouli ^[1] ; Marina,Papoutsaki ^[1] ; Maria,Politou ^[1] ; Pantelis,Panagakis ^[3] ; Angeliki,Befon ^[3] ; Fiori,Kousta ^[3] ; Eleni,Lazou ^[3] ; Vasiliki,Chasapi ^[3] ; Alexander,Stratigos ^[1] ; Electra,Nicolaidou ^[1]

作者单位： 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, I. Dragoumi 5, Athens, 161 21, Greece. ^[1] 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, I. Dragoumi 5, Athens, 161 21, Greece. giannhskmpr@gmail.com. ^[2] Department of Dermatology and Venereology NHS, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece. ^[3]

关键词 Interleukin-23 Obesity Psoriasis Risankizumab